TrialCancer research and treatment2022

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer.

Eo Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.